Author:
Liu Qi,Zhang Cheng,Ding Xianting,Deng Hui,Zhang Daming,Cui Wei,Xu Hongwei,Wang Yingwei,Xu Wanhai,Lv Lei,Zhang Hongyu,He Yinghua,Wu Qiong,Szyf Moshe,Ho Chih-Ming,Zhu Jingde
Publisher
Springer Science and Business Media LLC
Reference62 articles.
1. Peter E. C., Neeraj A. et al. National Comprehensive Cancer Network - NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer. (1. 2013). Available at: http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. (Accessed: 4th October 2013).
2. Ismael, G. F., Rosa, D. D., Mano, M. S. & Awada, A. Novel cytotoxic drugs: old challenges, new solutions. Cancer Treat Rev. 34, 81–91, S0305-7372(07)00102-8 (2008).
3. Borisy, A. A. et al. Systematic discovery of multicomponent therapeutics. Proceedings of the National Academy of Sciences of the United States of America. 100, 7977–7982, 10.1073/pnas.1337088100 (2003).
4. DeVita, V. T. & Schein, P. S. The use of drugs in combination for the treatment of cancer: rationale and results. N Engl J Med. 288, 998–1006, 10.1056/NEJM197305102881905 (1973).
5. Al-Lazikani, B., Banerji, U. & Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 30, 679–692, nbt.2284 (2012).
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献